跳轉至內容
Merck

Adenine phosphoribosyltransferase deficiency.

Clinical journal of the American Society of Nephrology : CJASN (2012-06-16)
Guillaume Bollée, Jérôme Harambat, Albert Bensman, Bertrand Knebelmann, Michel Daudon, Irène Ceballos-Picot
摘要

Complete adenine phosphoribosyltransferase (APRT) deficiency is a rare inherited metabolic disorder that leads to the formation and hyperexcretion of 2,8-dihydroxyadenine (DHA) into urine. The low solubility of DHA results in precipitation of this compound and the formation of urinary crystals and stones. The disease can present as recurrent urolithiasis or nephropathy secondary to crystal precipitation into renal parenchyma (DHA nephropathy). The diagnostic tools available-including stone analysis, crystalluria, and APRT activity measurement-make the diagnosis easy to confirm when APRT deficiency is suspected. However, the disease can present at any age, and the variability of symptoms can present a diagnostic challenge to many physicians. The early recognition and treatment of APRT deficiency are of crucial importance for preventing irreversible loss of renal function, which still occurs in a non-negligible proportion of cases. This review summarizes the genetic and metabolic mechanisms underlying stone formation and renal disease, along with the diagnosis and management of APRT deficiency.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
腺嘌呤, ≥99%
Sigma-Aldrich
腺嘌呤, BioReagent, suitable for cell culture
Sigma-Aldrich
腺嘌呤, BioReagent, suitable for plant cell culture, ≥99%
Supelco
腺嘌呤, Pharmaceutical Secondary Standard; Certified Reference Material
腺嘌呤, European Pharmacopoeia (EP) Reference Standard